Conditioning with Fludarabine-Busulfan versus Busulfan-Cyclophosphamide Is Associated with Lower aGVHD and Higher Survival but More Extensive and Long Standing Bone Marrow Damage

Figure 2

aGVHD manifestations, survival, and aGVHD clinical scores. (a) Weight loss started after conditioning and bone marrow transplantation in allogeneic and syngeneic groups conditioned with Bu-Cy. (b) Weight loss started after conditioning and bone marrow transplantation in allogeneic and syngeneic groups conditioned with Flu-Bu. (c) Survival analysis of different treatment groups. (d) aGVHD clinical scores of allogeneic recipients. (e) Appearance of mice in Group A. (f–h). Appearance of allogeneically transplanted mice (conditioned with Bu-Cy). (i-j) Appearance of allogeneically transplanted mice (conditioned with Flu-Bu). Group A: Normal BALB/c in the same condition; Group B: BALB/c injected intraperitoneally with 0.0625 mL DMSO; Group C: BALB/c conditioned with Bu (100 mg/kg)-Cy (200 mg/kg); Group D: BALB/c conditioned with Bu (100 mg/kg)-Cy (200 mg/kg) and transplanted with bone marrow cells, spleen cells from BALB/c; Group E: BALB/c conditioned with Bu (100 mg/kg)-Cy (200 mg/kg) and transplanted with bone marrow cells, spleen cells from C57BL/6; Group F: BALB/c conditioned with Flu (500 mg/kg)-Bu (100 mg/kg); Group G: BALB/c conditioned with Flu (500 mg/kg)-Bu (100 mg/kg) and transplanted with bone marrow cells, spleen cells from BALB/c; Group H: BALB/c conditioned with Flu (500 mg/kg)-Bu (100 mg/kg) and transplanted with bone marrow cells, spleen cells from C57BL/6. All data are presented as mean ± s.e. for 3–7 animals in each group per time point. .

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)